Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103629
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103629
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103629
Table 1 Characteristics of patients with oesophagus cancer by insurance type and out-of-pocket ratio, mean ± SD/n (%)
| Variables | All (n = 2543) | By insurance type | By out-of-pocket ratio | ||||
| URBMI (n = 1871) | UEBMI (n = 672) | P value | ≤ 60% (n = 1450) | > 60% (n = 1093) | P value | ||
| Age | 65.46 ± 8.57 | 65.50 ± 8.21 | 65.36 ± 9.50 | 0.703 | 65.50 ± 9.07 | 65.41 ± 7.86 | 0.787 |
| Sex | < 0.001 | < 0.001 | |||||
| Male | 2088 (82.11) | 1465 (78.30) | 623 (92.71) | 1246 (85.93) | 842 (77.04) | ||
| Female | 455 (17.89) | 406 (21.70) | 49 (7.29) | 204 (14.07) | 251 (22.96) | ||
| Marriage | 0.245 | 0.498 | |||||
| Married | 2381 (93.63) | 1745 (93.27) | 636 (94.64) | 1353 (93.31) | 1028 (94.05) | ||
| Others | 162 (6.37) | 126 (6.73) | 36 (5.36) | 97 (6.69) | 65 (5.95) | ||
| Nation | 1.000 | 1.000 | |||||
| Han | 2519 (99.06) | 1853 (99.04) | 666 (99.11) | 1436 (99.03) | 1083 (99.09) | ||
| Other minority | 24 (0.94) | 18 (0.96) | 6 (0.89) | 14 (0.97) | 10 (0.91) | ||
| BMI | < 0.001 | 0.003 | |||||
| 18.5-23.9 | 1550 (60.95) | 1181 (63.12) | 369 (54.91) | 856 (59.03) | 694 (63.49) | ||
| ≥ 24 | 594 (23.36) | 424 (22.66) | 170 (25.30) | 336 (23.17) | 258 (23.60) | ||
| < 18.5 | 399 (15.69) | 266 (14.22) | 133 (19.79) | 258 (17.79) | 141 (12.90) | ||
| KPS | 83.68 ± 8.10 | 83.90 ± 7.74 | 83.06 ± 9.02 | 0.020 | 82.94 ± 8.44 | 84.66 ± 7.53 | < 0.001 |
| Base disease | < 0.001 | < 0.001 | |||||
| No | 2033 (79.94) | 1567 (83.75) | 466 (69.35) | 1109 (76.48) | 924 (84.54) | ||
| Yes | 510 (20.06) | 304 (16.25) | 206 (30.65) | 341 (23.52) | 169 (15.46) | ||
| Pathological | 0.297 | 0.365 | |||||
| Squamous cell carcinoma | 2453 (96.46) | 1800 (96.21) | 653 (97.17) | 1394 (96.14) | 1059 (96.89) | ||
| Others | 90 (3.54) | 71 (3.79) | 19 (2.83) | 56 (3.86) | 34 (3.11) | ||
| TNM | < 0.001 | < 0.001 | |||||
| I | 196 (7.71) | 156 (8.34) | 40 (5.95) | 66 (4.55) | 130 (11.89) | ||
| II | 634 (24.93) | 492 (26.30) | 142 (21.13) | 324 (22.34) | 310 (28.36) | ||
| III | 989 (38.89) | 734 (39.23) | 255 (37.95) | 584 (40.28) | 405 (37.05) | ||
| IV | 724 (28.47) | 489 (26.14) | 235 (34.97) | 476 (32.83) | 248 (22.69) | ||
| Radiotherapy | < 0.001 | < 0.001 | |||||
| No | 1554 (61.11) | 1214 (64.89) | 340 (50.60) | 627 (43.24) | 927 (84.81) | ||
| Yes | 989 (38.89) | 657 (35.11) | 332 (49.40) | 823 (56.76) | 166 (15.19) | ||
| Chemotherapy | 0.002 | < 0.001 | |||||
| No | 1488 (58.51) | 1129 (60.34) | 359 (53.42) | 712 (49.10) | 776 (71.00) | ||
| Yes | 1055 (41.49) | 742 (39.66) | 313 (46.58) | 738 (50.90) | 317 (29.00) | ||
| Surgery | 0.732 | < 0.001 | |||||
| No | 1365 (53.68) | 1000 (53.45) | 365 (54.32) | 852 (58.76) | 513 (46.94) | ||
| Yes | 1178 (46.32) | 871 (46.55) | 307 (45.68) | 598 (41.24) | 580 (53.06) | ||
| Immunotherapy | 0.000 | 0.027 | |||||
| No | 2332 (91.70) | 1740 (93.00) | 592 (88.10) | 1314 (90.62) | 1018 (93.14) | ||
| Yes | 211 (8.30) | 131 (7.00) | 80 (11.90) | 136 (9.38) | 75 (6.86) | ||
| Targeted | < 0.001 | < 0.001 | |||||
| No | 2450 (96.34) | 1827 (97.65) | 623 (92.71) | 1372 (94.62) | 1078 (98.63) | ||
| Yes | 93 (3.66) | 44 (2.35) | 49 (7.29) | 78 (5.38) | 15 (1.37) | ||
| FIB | < 0.001 | 0.006 | |||||
| ≤ 3.66 | 1635 (64.29) | 1265 (67.61) | 370 (55.06) | 899 (62.00) | 736 (67.34) | ||
| > 3.66 | 908 (35.71) | 606 (32.39) | 302 (44.94) | 551 (38.00) | 357 (32.66) | ||
| β2 microglobulin | 0.000 | 0.032 | |||||
| ≤ 3.62 | 2246 (88.32) | 1679 (89.74) | 567 (84.38) | 1263 (87.10) | 983 (89.94) | ||
| > 3.62 | 297 (11.68) | 192 (10.26) | 105 (15.62) | 187 (12.90) | 110 (10.06) | ||
| LDH | 0.260 | 0.280 | |||||
| ≤ 236.4 | 2228 (87.61) | 1648 (88.08) | 580 (86.31) | 1261 (86.97) | 967 (88.47) | ||
| > 236.4 | 315 (12.39) | 223 (11.92) | 92 (13.69) | 189 (13.03) | 126 (11.53) | ||
| PLR | 0.022 | 0.024 | |||||
| ≤ 222.22 | 2082 (81.87) | 1552 (82.95) | 530 (78.87) | 1165 (80.34) | 917 (83.90) | ||
| > 222.22 | 461 (18.13) | 319 (17.05) | 142 (21.13) | 285 (19.66) | 176 (16.10) | ||
| LMR | < 0.001 | < 0.001 | |||||
| ≤ 3.18 | 1181 (46.44) | 812 (43.40) | 369 (54.91) | 718 (49.52) | 463 (42.36) | ||
| > 3.18 | 1362 (53.56) | 1059 (56.60) | 303 (45.09) | 732 (50.48) | 630 (57.64) | ||
| NLR | < 0.001 | < 0.001 | |||||
| ≤ 5.28 | 2178 (85.65) | 1647 (88.03) | 531 (79.02) | 1201 (82.83) | 977 (89.39) | ||
| > 5.28 | 365 (14.35) | 224 (11.97) | 141 (20.98) | 249 (17.17) | 116 (10.61) | ||
| ALB/GLB | 0.006 | 0.171 | |||||
| ≤ 1.08 | 436 (17.15) | 297 (15.87) | 139 (20.68) | 262 (18.07) | 174 (15.92) | ||
| > 1.08 | 2107 (82.85) | 1574 (84.13) | 533 (79.32) | 1188 (81.93) | 919 (84.08) | ||
| CD4/CD8 | 0.394 | < 0.001 | |||||
| ≤ 1.78 | 1484 (58.36) | 1082 (57.83) | 402 (59.82) | 899 (62.00) | 585 (53.52) | ||
| > 1.78 | 1059 (41.64) | 789 (42.17) | 270 (40.18) | 551 (38.00) | 508 (46.48) | ||
- Citation: Wu XL, Li XS, Cheng JH, Deng LX, Hu ZH, Qi J, Lei HK. Oesophageal cancer-specific mortality risk and public health insurance: Prospective cohort study from China. World J Gastrointest Oncol 2025; 17(4): 103629
- URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103629.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103629